Recombinant Human KRAS protein (ab96817)

Overview

Description

  • NatureRecombinant
  • SourceEscherichia coli
  • Amino Acid Sequence
    • AccessionP01116-2
    • SpeciesHuman
    • SequenceMGSSHHHHHH SSGLVPRGSH MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG HEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHHYREQI KRVKDSEDVP MVLVGNKCDL PSRTVDTKQA QDLARSYGIP FIETSAKTRQ GVDDAFYTLV REIRKHKEKM SKDGKKKKKK SKTKC
    • Molecular weight23 kDa including tags
    • Amino acids1 to 185
    • TagsHis tag N-Terminus
    • Additional sequence informationCorresponds to K-Ras4B (Isoform 2B)

Specifications

Our Abpromise guarantee covers the use of ab96817 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Mass Spectrometry

    SDS-PAGE

    Western blot

  • Mass spectrometry
    MALDI-TOF-TOF
  • Purity> 90 % SDS-PAGE.
    ab96817 is purified using conventional chromatography techniques.
  • FormLiquid
  • Additional notes

    Isoform 2B

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Preservative: None
    Constituents: 10% Glycerol, 0.1M Sodium chloride, 20mM Tris HCl, 1mM DTT, pH 8.0

General Info

  • Alternative names
    • c Ki ras2
    • c Kirsten ras protein
    • c-K-ras
    • c-Ki-ras
    • Cellular c Ki ras2 proto oncogene
    • Cellular transforming proto oncogene
    • CFC2
    • cK Ras
    • GTPase KRas
    • K RAS p21 protein
    • K RAS2A
    • K RAS2B
    • K RAS4A
    • K RAS4B
    • K-Ras 2
    • KI RAS
    • Ki-Ras
    • KIRSTEN MURINE SARCOMA VIRUS 2
    • Kirsten rat sarcoma 2 viral (v Ki ras2) oncogene homolog
    • Kirsten rat sarcoma viral oncogene homolog
    • KRAS
    • KRAS proto oncogene, GTPase
    • KRAS1
    • KRAS2
    • N-terminally processed
    • NS
    • NS3
    • Oncogene KRAS2
    • p21ras
    • PR310 c K ras oncogene
    • PR310 cK ras oncogene
    • RALD
    • RASK_HUMAN
    • RASK2
    • Transforming protein p21
    • v Ki ras2 Kirsten rat sarcoma 2 viral oncogene homolog
    • v Ki ras2 Kirsten rat sarcoma viral oncogene homolog
    see all
  • FunctionRas proteins bind GDP/GTP and possess intrinsic GTPase activity.
  • Involvement in diseaseDefects in KRAS are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.
    Defects in KRAS are a cause of juvenile myelomonocytic leukemia (JMML) [MIM:607785]. JMML is a pediatric myelodysplastic syndrome that constitutes approximately 30% of childhood cases of myelodysplastic syndrome (MDS) and 2% of leukemia. It is characterized by leukocytosis with tissue infiltration and in vitro hypersensitivity of myeloid progenitors to granulocyte-macrophage colony stimulating factor.
    Defects in KRAS are the cause of Noonan syndrome type 3 (NS3) [MIM:609942]. Noonan syndrome (NS) [MIM:163950] is a disorder characterized by dysmorphic facial features, short stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a bleeding diathesis. It is a genetically heterogeneous and relatively common syndrome, with an estimated incidence of 1 in 1000-2500 live births. Rarely, NS is associated with juvenile myelomonocytic leukemia (JMML). NS3 inheritance is autosomal dominant.
    Defects in KRAS are a cause of gastric cancer (GASC) [MIM:613659]; also called gastric cancer intestinal or stomach cancer. Gastric cancer is a malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.
    Note=Defects in KRAS are a cause of pylocytic astrocytoma (PA). Pylocytic astrocytomas are neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors.
    Defects in KRAS are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
    Note=KRAS mutations are involved in cancer development.
  • Sequence similaritiesBelongs to the small GTPase superfamily. Ras family.
  • Cellular localizationCell membrane.
  • Information by UniProt

Recombinant Human KRAS protein images

  • 15% SDS-PAGE showing ab96817 at approximately 23.2 kDa (3 µg).
  • MALTI-TOF result: of 23253.422 Da for Human KRAS Protein.


  • Developed using the ECL technique

    Performed under reducing conditions.

    This blot was produced using a 4-12% Bis-tris gel under the MES buffer system. The gel was run at 200V for 35 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 5% Bovine Serum Albumin before being incubated with ab84573 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution.

References for Recombinant Human KRAS protein (ab96817)

ab96817 has not yet been referenced specifically in any publications.

Product Wall

Thank you for contacting us and your interest in our products.

The KRAS protein (ab96817) is provided as the sequence described in the "Sequence" description expressed in E. coli:

MGSSHHHHHH SSGLVPRGSH MTEYKLVVVG AGGVGKSAL...

Read More

Thank you for contacting us.

The ab90765 and ab90768 are also active proteins and can be used in functional assays.

ab96817 is not an active protein.

Please note that we haven't tried these proteins in functional assay so...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"